BH_NonClinical_Pharmacy_Car-T

CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells.

The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products

At the time of writing it is only offered at 8 sites across the UK.

The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.

The price paid to the supplier with be capped at NICE / NHS England approved list prices.